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When pharmacy apprentice Friedrich Wilhelm Adam
Sertürner (1783–1841) was the first person to report in
1806 on the isolation of a water-insoluble crystalline
substance from opium, there was no talk at the time about
innovation. The isolation  of the substance named morphine
(consistent with the god of dreams, Morpheus, in Greek
mythology) by him in 1817 was nevertheless an innovative
proceeding without a doubt. Morphine has maintained the
worth of its price ever since.
Assessing the price of a drug is one of the biggest prob-
lems in modern pharmaceutical policy-making. How do we
distinguish a true innovation in order to find out what could
be paid for it? It was suggested recently that “the only correct
end result of a successful innovation process is a product or a
service that sells like hot cakes”. 1 This is not a suitable way
of referring to a drug innovation.
In recent decades the concepts of innovation and innova-
tiveness have been used fairly liberally in the pharmaceutical
sector. Among the nearly 50 new active substances intro-
duced on to the world markets every year only a few are
considered to be real breakthrough inventions or innova-
tions. As Anna Karjalainen in her paper in this journal sug-
gests, the inflation of the concept of drug innovation may be
influenced by various viewpoints taken in reviewing the
issue. It is, in fact, rather self-evident that the viewpoint of
society (often that of the payer) should be dissimilar from
that of the pharmaceutical industry (developer), researcher
(scientist) or doctor and patient (consumers).
Europe can be seen to have lost to the United States of
America some of its standing in the generation of pharma-
ceutical inventions. Measures to restore the competitiveness
of European pharmaceutical research and the European
industry have been sought in the EU for about a decade.
The legislation covering orphan drugs and paediatric medi-
cines serves as an example. Patent regulations, accelerated
authorisation processes, exclusive rights and increasing pub-
lic research subsidies are some of the measures aimed at
speeding up the generation of drug innovations and increas-
ing the competitiveness of the pharmaceutical industry.
The pricing and reimbursement systems of  medicines
have become special problems in Europe. National health
care systems, their financing and that of social insurance
(e.g. the reimbursement system) fall into the domain of
national sovereignty. It is therefore difficult to promote com-
petitiveness and innovativeness at the European level unless
agreement can be reached on uniform prices and pharma-
ceutical reimbursement policies. The truth is in fact that in
practice a medicinal product is not on the markets and in
use until it has gained approval in the reimbursement
system.
Before a decision can be made on the refundable cost of
a drug, the therapeutic value of the drug should be
ascertained in relation to the existing available pharmaceuti-
cal therapy. Efforts are at present being made in the Europ-
ean Commission project Pharmaceutical Forum to clarify the
concepts of relative effectiveness and additional therapeutic
value. Measures should be agreed upon which would help
the payer and the consumer to find out about the degree of
innovativeness associated with a new drug. It is hoped that
progress is made in the EU on these issues. This would be
for the benefit of society and the patients as well as the
pharmaceutical industry.
A common understanding could thereby be reached in
order to distinguish the true drug innovations from pharma-
ceutical novelties of lesser value. More developed societies are
prepared to pay for ever more costly therapies as long as
their additional therapeutic value for the correct patient
group can be adequately ascertained. Plenty of new drugs are
being developed and some of them will certainly deserve the
distinction of being innovations.
Morphine isolated by Sertürner had the same fate as
innovations usually have. Another innovation was required
until the road was open for the extensive use of morphine in
pain treatment. The innovation involved the introduction of
a syringe and a hollow hypodermic needle in the 1850s.
Sertürner did not manage to enjoy the success in his
lifetime, neither did he in his own opinion receive adequate
acknowledgement for his own discovery.
1 Ruonala J: Yritykset innovoivat, eivät kansakunnat. Presso 27.10.2006.
Pharmaceutical  innovations – but how much
should we pay for them?
The state of drug development has
been a matter for concern for quite
some time. Only a couple of pharma-
ceuticals called breakthrough drugs (1)
have been launched on to the market
in recent years, while the pharmaceuti-
cal industry is blamed for cashing in
on it by producing minute modifica-
tions of old medicinal products. Para-
doxically, the innovativeness of phar-
maceutical companies appears to have
declined coincidentally with the boom
of investments into research and prod-
uct development. Despite the increased
investments in research and product
development, the number of drugs
defined as innovative has remained rel-
atively stable (about 20 annually) in
1990 to 2004 (2, 3).
With regard to the European eco-
nomical policy the pharmaceutical
industry is an important operator and
its decline in relation to the United
States of America and the rising Asian
states has not gone unnoticed by the
political media. As a result of the Lis-
bon strategy (4), support for European
innovativeness and competitiveness has
taken over the centre stage in EU poli-
tics. Despite the political will to do so,
prioritising the promotion of innova-
tiveness is difficult in member states
engaged in crises involving health care
costs. To support innovativeness with-
out becoming involved in insurmount-
able economical problems appears in
fact to require the ability to distinguish
the true innovations from the
multitude of minor modifications. It
is, however, difficult to define the
grade of innovativeness of medicinal
products.
Drug innovation
The definition of drug innovation
often varies according to the point of
view of the definer (5). A break-
through drug developed for the treat-
ment of a severe disease can be consid-
ered an innovation, but equally so can
an improvement in a product which
has been on the market for a long
time. According to one definition,
innovation can be seen as a technologi-
cal progress as a result of which either
a totally new product is generated, or
production costs can be reduced, or
the therapeutic value of an existing
drug is increased (6). In principle, the
difficulty of defining drug innovation
is in fact at the core of the whole prob-
lem: classifying a new drug as an inno-
vation guarantees a high price and
increases the profit margin of the phar-
maceutical industry. Accuracy in defin-
ition is nonetheless recommended,
since this is the only way to exert con-
trol on drug costs while investments
can be focused on treatments and
thereby generate true added value for
the patients.
Drug innovation and EU
The aim set by the EU in the Lisbon
strategy was to make an effort to
become  by the end of the decade the
most competitive and dynamic econo-
my based on information (4). The
concept of innovation may be consid-
ered to have been elevated to the cen-
tre stage of common European
politics. The G10 recommendations
(2002) also focused on the public
health standpoints (8). The EU phar-
maceutical policy has in fact always
represented a tug of war between the
interests of business and those of pub-
lic health (8). Innovation at the EU
level may in fact be seen as the synthe-
sis of European competitiveness and
supportive employment measures with
public health advancement.
Efforts are being made to support
the European innovativeness and com-
petitiveness through a variety of initia-
tives. However, the national decision-
maker’s attention is easily focused on
the costs instead of the support that
competitiveness requires. The payers
react to drug innovations from the
standpoint of cost control (5). The
European Union approach to the
problematic relationship between drug
innovations and costs is, for instance,
via the concepts of additional therap-
eutic value and relative effectiveness. A
drug which has additional therapeutic
value is hoped to rapidly be included
in the member state national
reimbursement systems (9).  The Euro-
pean Commission also aims to create
uniform assessment systems of relative
effectiveness which, it is hoped, will
lead to standard requirements and
increased competitiveness (10).
The discussions on innovation also
influence the work of the drug regula-
tory authorities. EMEA aims to facili-
tate innovation and stimulate research
(11) by means, for example, of
increased scientific consultation, accel-
erated marketing authorisation
processes relating to innovative drugs,
and innovative drug development
guidelines. The regulatory authorities
are balancing between ensuring drug
safety for patients and applying the
most recent achievements in science
and technology. Foolhardiness may
lead to safety risks, whereas excessive
caution slows down development and
the introduction of new therapies on
to the market (12). From the view-
point of the regulatory authority, drug
innovation can in fact be seen as the
combination of all these features: a sig-
nificant innovation creating additional
therapeutic value, good patient safety
and maintenance of competitiveness in
the pharmaceutical industry.
Drug innovation and the
patient
According to the definition by the
World Health Organisation (WHO),
innovation in the public health sector
implies the introduction of such new
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ideas, practices and programmes as will
improve the health of the population
(13). From the patient’s point of view
a drug to treat a disease for which
there has formerly been no effective
treatment available is an innovation. A
new indication of a product already
available on the market may also con-
vey additional value for the patient (6).
Issues relating to the safety of new
medicinal products, i.e. the acceptable
level of risk, are constantly being dis-
cussed. Each patient defines the
acceptable level of risk and cost on his
or her own premises. A seriously ill
patient is readier to take a higher risk
and pay a higher price for the
treatment than a patient who is less
seriously ill. The proportion of the cost
for which the patient is responsible is
in fact likely to grow along with the
drug cost crisis in society. The number
of treatment alternatives also affects
the level of acceptable risk: with no
alternatives available, even a high risk
associated with the only drug available
will find acceptance (5). A rapid intro-
duction of a breakthrough drug on to
the market can therefore be considered
an advantage to the patient, despite
the fact that possible adverse effects
may have gone unnoticed if it has hap-
pened that the extent and duration of
clinical trials have had to be compro-
mised due to a fast-track procedure in
the marketing authorisation approval. 
Concern has been expressed about
the emphasis given to the business
point of view. The developed countries
should shoulder the responsibility for
the development of medical treatment
for a number of diseases afflicting the
developing countries, because the prof-
it-focusing pharmaceutical industry
cannot be expected to show an interest
in the needs for medical treatment in
the developing countries (14). The sup-
port shown by the public sector is also
of great importance for the develop-
ment of orphan and paediatric drugs.
Drug innovation and the 
pharmaceutical industry
The pharmaceutical industry aims to
generate a profit for its shareholders.
However, it appears to have become
ever more difficult to increase sales and
profits (15). Pharmaceutical companies
can be considered to be responsible,
not only to their various owners, but
also to the general public using its
products. Pressures are generated by
authorities’ demands and
reimbursement system practices. These
internal and external pressures may
exhaust the innovative ability of the
industry (5). The continuously grow-
ing need for resources in drug develop-
ment is also undermining its possibili-
ties, as the increased costs will lead to a
situation where the drug companies
will invest in development projects
with the highest profits possible (5).
From the standpoint of the
pharmaceutical industry, therefore,
innovation shows itself to be a compli-
cated aggregation of the
investment/product relationship,
patient satisfaction and safety, the
additional therapeutic value expected
by national drug reimbursement sys-
tems, and a moderate price.
The implications for the pharma-
ceutical industry from the multitude of
public sector practices and decisions,
such as the uncertainty factors associat-
ed with drug reimbursement decisions,
can involve reduced innovativeness
(16). The problem is most salient in
Europe, where the reimbursement
decisions are made independently by
each member state. Many of the regu-
lations are considered to inhibit devel-
opment and to be costly to implement.
Several public sector adopted practices
are also considered outdated and are
not found to offer adequate incentives
for innovation, whereas the uncertain-
ty created by quick practical changes
again will take its toll on the capacity
for innovation (16).
Discussion
Relatively few medicinal substances
classified as innovative have been
introduced on to the market in recent
years. Besides Europe, concern for the
declining innovativeness also affects
Japan and the United States of Ameri-
ca. Common to the projects dedicated
to improving the effectivity of innova-
tiveness appears to be the increasing
collaboration between various opera-
tors, both private and public.
In Europe, efforts are being made
to solve the member states’ drug cost
crisis by introducing uniform defini-
tion criteria for the relative effective-
ness and added therapeutic value of
the drugs. Even though some type of
hierarchy can be built on the strength
of therapeutic progress, classification of
medical treatment is nevertheless often
complicated and ethically questionable:
how should we define, on the one
hand, society’s responsibility for the
individual, and the individual’s respon-
sibility for himself/herself on the
other? Drug costs continue to grow
and will eventually lead to prioritising
among treatment costs.
Innovativeness and competitiveness
continue to remain the key topics in
EU politics while there is a wide selec-
tion of measures for supporting innov-
ativeness. The danger is, however, that
too many various operators are focus-
ing on too many issues at the same
time, which may lead to a lack of co-
ordination, diffusion of plans and
wastage of the European tax resources.
Among the various concepts of
drug innovation, is it possible to reach
a universally fruitful synthesis? This is
probably feasible, and also preferable
by all parties. Nor is there any doubt
that all involved will have to compro-
mise. Societies should accept the rising
drug costs, in which case correct
targeting of the funds available is of
the utmost importance. Primary care
especially is often forced to give prefer-
ence to less costly generic drugs to
make it possible to compensate for
true innovations at a rate which is ade-
quate also from the industry’s view-
point. Patients should accept a higher
excess and a possibly increased safety
risk associated with drugs granted a
fast-track marketing authorisation,
which the authorities will take into
consideration in the process of grant-
ing marketing authorisations. The
pharmaceutical industry will have to
accept the growing generic com-
petition, together with profits lower
than before. These compromises would
clarify the meaning of the term ‘drug
innovation’, which has become vague.
A successful drug innovation can con-
sequently be regarded as a synthesis of
a significant reform which generates
additional therapeutic value, a high
patient safety profile and the safe-
guarding of pharmaceutical industry
competition and jobs. In that way it
would also benefit all the parties
involved.
See literature on page 37
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